Demyelinating Neurological Adverse Events following the Use of Anti-TNF-α Agents: A Double-Edged Sword

BACKGROUND: Tumor necrosis factor antagonists (anti-TNF-α) are an established therapeutic option for several autoimmune and inflammatory bowel diseases. Despite their clinical effectiveness, neurological adverse events have been reported, and literature data suggest a potential role of anti-TNF-α in...

Descripción completa

Detalles Bibliográficos
Autores principales: Gharib, Miral H., AlKahlout, Mohamed Awni, Garcia Canibano, Beatriz, Theophiel Deleu, Dirk, Malallah AlEssa, Hani, AlEmadi, Samar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8920694/
https://www.ncbi.nlm.nih.gov/pubmed/35296124
http://dx.doi.org/10.1155/2022/3784938

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8920694/
https://www.ncbi.nlm.nih.gov/pubmed/35296124
http://dx.doi.org/10.1155/2022/3784938

Ejemplares similares